Evidence map›Paper›PMID 19681869›Full record

ArticleBritish journal of pharmacology2009

Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.

D Altavilla, F Squadrito, A Bitto, F Polito, B P Burnett, V Di Stefano, L Minutoli

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Agarwood-The Fragrant Molecules of a Wounded Tree.Molecules (Basel, Switzerland) · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018
    Article
  12. Flavocoxid exerts a potent antiviral effect against hepatitis B virus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Flavocoxid attenuates gentamicin-induced nephrotoxicity in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2015
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

D AltavillaDepartment of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy.
F Squadrito
A Bitto
F Polito
B P Burnett
V Di Stefano
L Minutoli
University of Messina · ITPrimus Consulting (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe flavonoids, baicalin and catechin, from Scutellaria baicalensis and Acacia catechu, respectively, have been used for various clinical applications. Flavocoxid is a mixed extract containing baicalin and catechin, and acts as a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (LOX) enzymes. The anti-inflammatory activity, measured by protein and gene expression of inflammatory markers, of flavocoxid in rat peritoneal macrophages stimulated with Salmonella enteritidis lipopolysaccharide (LPS) was investigated. EXPERIMENTAL APPROACH: LPS-stimulated (1 microg.mL(-1)) peritoneal rat macrophages were co-incubated with different concentrations of flavocoxid (32-128 microg.mL(-1)) or RPMI medium for different incubation times. Inducible COX-2, 5-LOX, inducible nitric oxide synthase (iNOS) and inhibitory protein kappaB-alpha (IkappaB-alpha) levels were evaluated by Western blot analysis. Nuclear factor kappaB (NF-kappaB) binding activity was investigated by electrophoretic mobility shift assay. Tumour necrosis factor-alpha (TNF-alpha) gene and protein expression were measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assay respectively. Finally, malondialdehyde (MDA) and nitrite levels in macrophage supernatants were evaluated. KEY

resultsLPS stimulation induced a pro-inflammatory phenotype in rat peritoneal macrophages. Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression. PGE(2) and LTB(4) levels in culture supernatants were consequently decreased. Flavocoxid also prevented the loss of IkappaB-alpha protein (LPS = 1.9 +/- 0.2; flavocoxid = 7.2 +/- 1.6 integrated intensity), blunted increased NF-kappaB binding activity (LPS = 9.2 +/- 2; flavocoxid = 2.4 +/- 0.7 integrated intensity) and the enhanced TNF-alpha mRNA levels (LPS = 8 +/- 0.9; flavocoxid = 1.9 +/- 0.8 n-fold/beta-actin) induced by LPS. Finally, flavocoxid decreased MDA, TNF and nitrite levels from LPS-stimulated macrophages. CONCLUSION AND IMPLICATIONS: Flavocoxid might be useful as a potential anti-inflammatory agent, acting at the level of gene and protein expression.

Indexed as

Lipoxygenase InhibitorsAnimalsCatechinCell SurvivalCyclooxygenase 2Cyclooxygenase InhibitorsDinoprostoneDrug CombinationsEnzyme-Linked Immunosorbent AssayFlavonoidsI-kappa B ProteinsLipopolysaccharidesMacrophages, PeritonealMaleNF-KappaB Inhibitor alphaNitric Oxide Synthase Type IIbaicalinCatechinCyclooxygenase 2Cyclooxygenase InhibitorsDinoprostoneDrug CombinationsFlavonoidsI-kappa B ProteinsLipopolysaccharidesLipoxygenase InhibitorsNF-KappaB Inhibitor alphaNfkbia protein, ratNitric Oxide Synthase Type IITumor Necrosis Factor-alpha

Identifiers

PMID19681869
PMCPMC2765324
OpenAlexW2096179188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.